The adoption of a new technology into basic research, and industrial and clinical settings
requires rigorous testing to build confidence in the reproducibility, reliability, robustness, and …

Improved model systems to predict drug efficacy, interactions, and drug-induced kidney
injury (DIKI) are crucially needed in drug development. Organ-on-a-chip technology is a …

Pharmaceutical drug screening and research into diseases call for significant improvement
in the effectiveness of current in vitro models. Better models would reduce the likelihood of …

Kidneys are critical for the elimination of many drugs and metabolites via the urine, filtering
waste and maintaining proper fluid and electrolyte balance. Emerging technologies …

The renal proximal tubule epithelium is responsible for active secretion of endogenous and
exogenous waste products from the body and simultaneous reabsorption of vital compounds …

Current developments in tissue engineering and microtechnology fields have allowed the
proposal of pertinent tools, microchips, to investigate in vitro toxicity. In the framework of the …

The organs-on-a-chip technology has shown strong promise in mimicking the complexity of
native tissues in vitro and ex vivo, and recently significant advances have been made in …

Kidney toxicity is one of the most frequent adverse events reported during drug
development. The lack of accurate predictive cell culture models and the unreliability of …

Progress in understanding kidney disease mechanisms and the development of targeted
therapeutics have been limited by the lack of functional in vitro models that can closely …

Microphysiological systems (organs-on-chips, tissue chips) are devices designed to
recapitulate human physiology that could be used to better understand drug responses not …